| EN
Simcere has consistently maintained a high level of investment in innovation and R&D. Over the past five years, the company has invested nearly CNY 9 billion in research and development.
With innovation centers in Nanjing, Shanghai, Beijing, and Boston, Simcere has built a comprehensive R&D system that integrates drug discovery, preclinical development, clinical trials, and drug registration. The company currently has over 60 projects in its new drug development pipeline.
Additionally, Simcere has assembled an R&D team of over 1,000 professionals, more than 70% of whom hold master's or doctoral degrees, and over 10% have international experience.

Global R&D Center Layout

Boston R&D Center

Nanjing R&D Center

Shanghai R&D Center

R&D Pipeline

We have nearly 60 innovative product candidates in different stages of development, among which over 10 product candidates had obtained the IND approval or were at clinical stage.

MORE+

Massachusetts is home to 19% of the top pharmaceutical product pipelines in the United States and 9% globally. The state capital, Boston, in particular holds a dominating position in the global life sciences community.

Simcere’s Boston R&D Center focuses on the world's cutting-edge cell and gene therapies, and with its team of pioneering scientists, it remains dedicated to building a world-class R&D center. Utilizing the world's state-of-the-art technologies, we are rapidly building several cutting-edge technology platforms for cell and gene therapies and thereby making the Boston R&D Center a powerful pipeline driver for Simcere through the institute’s fast and efficient project promotion system.